Anemia is a finding, not a diagnosis. The hemoglobin tells you there is a problem. The MCV, reticulocyte count, iron studies, and smear tell you what the problem is. Use the framework — do not skip steps.
CLINICAL PRINTABLE
Coming Soon.
A one-page Anemia First-Pass clinical reference is on the way.
1 · Start With the MCV
The first-pass interpretation of anemia uses MCV to organize the differential into three categories: microcytic (MCV below 80 fL), normocytic (MCV 80–100 fL), and macrocytic (MCV above 100 fL). This is not a diagnosis — it is a framework for the next step.
Microcytic anemia (MCV below 80 fL) points toward iron deficiency (the most common cause worldwide), thalassemia (alpha or beta), anemia of chronic disease (occasionally microcytic), and sideroblastic anemia. Iron studies — serum iron, TIBC, transferrin saturation, and ferritin — are the first-line targeted tests.
Normocytic anemia (MCV 80–100 fL) has the broadest differential: early iron deficiency (before microcytosis develops), anemia of chronic disease, CKD-related anemia, hemolysis, acute blood loss, mixed deficiencies (iron + B12/folate averaging to a normal MCV), and marrow disorders. The reticulocyte count is the key next step.
Macrocytic anemia (MCV above 100 fL) points toward B12 or folate deficiency (megaloblastic), alcohol use, liver disease, hypothyroidism, medications (methotrexate, hydroxyurea, azathioprine, zidovudine), and reticulocytosis (reticulocytes are larger than mature RBCs). Distinguishing megaloblastic from non-megaloblastic macrocytosis guides the workup.
2 · Reticulocyte Count — Hypoproliferative vs. Hyperproliferative
The reticulocyte count (or reticulocyte production index, RPI) is the second key step in anemia evaluation. It separates hypoproliferative anemia (the bone marrow is not responding appropriately) from hyperproliferative anemia (the marrow is responding — something is destroying or losing red cells faster than they can be replaced).
A low reticulocyte count or low RPI indicates hypoproliferative anemia: the marrow is not producing enough red cells. Causes include iron deficiency, B12 or folate deficiency, anemia of chronic disease, CKD (reduced EPO), marrow suppression from medications or chemotherapy, aplastic anemia, and marrow infiltration.
A high reticulocyte count or high RPI indicates hyperproliferative anemia: the marrow is responding to increased red cell destruction or loss. Causes include hemolysis (autoimmune, microangiopathic, hereditary) and acute blood loss. The marrow is working — the problem is upstream.
The reticulocyte production index corrects for the degree of anemia: RPI = (reticulocyte % × hematocrit / 45) / maturation factor. An RPI above 2–3 suggests an adequate marrow response (hyperproliferative); below 2 suggests an inadequate response (hypoproliferative). Many labs now report an absolute reticulocyte count, which is more straightforward to interpret.
3 · Iron Studies — Interpreting the Panel
Iron studies are essential for evaluating microcytic anemia and for distinguishing iron deficiency from anemia of chronic disease. The panel includes serum iron, TIBC (total iron-binding capacity), transferrin saturation, and ferritin.
Iron deficiency pattern: low serum iron, high TIBC, low transferrin saturation (below 16–20%), low ferritin. The high TIBC reflects the liver's upregulation of transferrin production in response to iron deficiency. The low ferritin is the most specific finding — ferritin below 30 ng/mL is highly specific for iron deficiency.
Anemia of chronic disease pattern: low serum iron, low or normal TIBC, low transferrin saturation, normal or elevated ferritin. The low TIBC reflects suppression of transferrin production by inflammatory cytokines. The normal or elevated ferritin reflects the acute-phase response — ferritin is an acute-phase reactant that rises with inflammation independent of iron stores.
The critical nuance: in a patient with both iron deficiency and chronic inflammation, ferritin may be normal or only mildly elevated despite true iron deficiency. In this setting, a transferrin saturation below 20% and a low serum iron are more reliable indicators of functional iron deficiency than ferritin alone. Soluble transferrin receptor (sTfR) is elevated in iron deficiency but not in anemia of chronic disease and can help distinguish the two in ambiguous cases.
4 · Hemolysis — Recognizing the Pattern
Hemolytic anemia has a specific laboratory signature that distinguishes it from other causes of normocytic or macrocytic anemia. The combination of elevated LDH, elevated indirect (unconjugated) bilirubin, low haptoglobin, and elevated reticulocyte count is the classic hemolysis panel.
Haptoglobin is the most sensitive marker of intravascular hemolysis — it binds free hemoglobin released from lysed red cells and is cleared by the liver. In significant hemolysis, haptoglobin is consumed and falls to undetectable levels. LDH is released from lysed red cells and rises. Indirect bilirubin rises from the breakdown of hemoglobin.
Peripheral smear is essential in suspected hemolysis. Schistocytes (fragmented red cells) suggest microangiopathic hemolytic anemia (MAHA) — TTP, HUS, DIC, or mechanical valve hemolysis. Spherocytes suggest autoimmune hemolytic anemia (AIHA) or hereditary spherocytosis. Sickle cells suggest sickle cell disease. Bite cells suggest G6PD deficiency.
The direct antiglobulin test (DAT, or direct Coombs test) distinguishes immune-mediated from non-immune hemolysis. A positive DAT indicates antibodies or complement on the red cell surface — consistent with AIHA, drug-induced hemolysis, or transfusion reaction. A negative DAT suggests non-immune hemolysis — microangiopathic, hereditary, or mechanical.
5 · B12 and Folate Deficiency — Megaloblastic Anemia
B12 and folate deficiency cause megaloblastic anemia through impaired DNA synthesis — cells cannot divide normally, producing large, abnormal red cell precursors (megaloblasts) that are destroyed in the marrow (ineffective erythropoiesis). The result is macrocytic anemia with hypersegmented neutrophils on peripheral smear (5 or more lobes in a neutrophil, or any neutrophil with 6 or more lobes).
B12 deficiency has important neurological consequences that folate deficiency does not: subacute combined degeneration of the spinal cord (posterior and lateral column demyelination), causing paresthesias, ataxia, and cognitive changes. Neurological symptoms can precede or occur without anemia. Treating B12 deficiency with folate alone can correct the anemia but allow neurological damage to progress — this is why distinguishing B12 from folate deficiency matters.
Causes of B12 deficiency include pernicious anemia (autoimmune destruction of gastric parietal cells, reducing intrinsic factor production), gastric surgery, strict veganism (B12 is found only in animal products), and malabsorption (Crohn's disease, ileal resection, bacterial overgrowth). Metformin impairs B12 absorption through an uncertain mechanism and is an underrecognized cause of B12 deficiency in diabetic patients.
Causes of folate deficiency include poor dietary intake (folate is found in leafy green vegetables and is heat-labile — destroyed by cooking), malabsorption, increased demand (pregnancy, hemolytic anemia, rapid cell turnover), and medications that impair folate metabolism (methotrexate, trimethoprim, phenytoin).
Apply It · Patient Scenario
A 45-year-old woman with rheumatoid arthritis on methotrexate presents with fatigue and dyspnea on exertion for 2 months. CBC: Hgb 9.2 g/dL, MCV 88 fL, RDW elevated. Reticulocyte count is low. Ferritin is 95 ng/mL. Serum iron is low. Transferrin saturation is 14%.
What is the most likely cause of her anemia and what is the next step?
A. Anemia of chronic disease from rheumatoid arthritis — no further workup needed
B. Iron deficiency anemia — start oral iron supplementation
C. Mixed iron deficiency and anemia of chronic disease — treat iron deficiency and reassess
D. Methotrexate-induced megaloblastic anemia — check B12 and folate, add folic acid
ANSWER
C. Mixed iron deficiency and anemia of chronic disease — treat iron deficiency and reassess.
RATIONALE
The pattern is classic for mixed iron deficiency and anemia of chronic disease. The MCV is normal (88 fL) — but the elevated RDW suggests a heterogeneous red cell population, consistent with two opposing processes (microcytic iron deficiency and normocytic/macrocytic anemia of chronic disease) averaging to a normal MCV. The low transferrin saturation (14%) and low serum iron indicate functional iron deficiency. The ferritin of 95 ng/mL appears normal — but ferritin is an acute-phase reactant, and in a patient with active rheumatoid arthritis, a ferritin of 95 ng/mL may still represent iron deficiency.
The low reticulocyte count confirms hypoproliferative anemia — the marrow is not responding. Iron deficiency is the treatable component. Start oral iron supplementation and recheck CBC and iron studies in 4–6 weeks. Also check B12 and folate given methotrexate use — methotrexate impairs folate metabolism and can cause megaloblastic changes. Folic acid supplementation is standard with methotrexate.
Clinical Pearl: In a patient with chronic inflammation, a normal ferritin does not exclude iron deficiency. Transferrin saturation below 20% is a more reliable indicator of functional iron deficiency in this setting.
NOW CHANGE ONE DETAIL
Same patient. MCV is now 108 fL. Peripheral smear shows hypersegmented neutrophils. She reports paresthesias in her hands and feet.
UPDATED REASONING
Macrocytic anemia with hypersegmented neutrophils is megaloblastic anemia until proven otherwise. Methotrexate impairs folate metabolism and can cause megaloblastic changes. The paresthesias suggest possible B12 deficiency with neurological involvement — B12 deficiency causes subacute combined degeneration that folate deficiency does not.
Check B12 and folate levels immediately. If B12 is low, replace B12 first — treating with folate alone can correct the anemia but allow neurological damage to progress. Ensure adequate folic acid supplementation with methotrexate. Consider whether methotrexate dose adjustment is needed.
Understand It · The Nuance
The most common errors in anemia evaluation are stopping at the MCV, trusting a normal ferritin in the setting of inflammation, and missing mixed deficiencies that produce a deceptively normal MCV.
MCV organizes the differential — it does not end it
Microcytic anemia (MCV below 80 fL) points toward iron deficiency, thalassemia, anemia of chronic disease (occasionally), and sideroblastic anemia. Normocytic anemia (MCV 80–100 fL) has the broadest differential: early iron deficiency, anemia of chronic disease, CKD, hemolysis, acute blood loss, and mixed deficiencies. Macrocytic anemia (MCV above 100 fL) points toward B12 or folate deficiency, alcohol, liver disease, hypothyroidism, medications, and reticulocytosis. Mixed deficiencies can produce a normal MCV with an elevated RDW.
Reticulocyte count separates hypoproliferative from hyperproliferative anemia
A low reticulocyte count (or low reticulocyte production index) indicates the bone marrow is not responding appropriately — hypoproliferative anemia from iron deficiency, B12/folate deficiency, anemia of chronic disease, CKD, or marrow suppression. A high reticulocyte count indicates the marrow is responding — hyperproliferative anemia from hemolysis or acute blood loss. This distinction drives the next step in the workup.
Anemia of chronic disease is a diagnosis of exclusion in the right context
Anemia of chronic disease (now often called anemia of inflammation) is caused by inflammatory cytokines that suppress erythropoiesis, reduce iron availability, and blunt EPO response. It is typically normocytic or mildly microcytic, with low serum iron, low TIBC, and normal or elevated ferritin. It is common in patients with chronic infection, autoimmune disease, malignancy, and CKD — but iron deficiency must be excluded before attributing anemia to inflammation.
Ferritin is an acute-phase reactant
Ferritin is elevated by inflammation, infection, liver disease, and malignancy — independent of iron stores. A normal or elevated ferritin does not exclude iron deficiency in a patient with concurrent inflammation. In this setting, transferrin saturation below 20% and a low serum iron are more reliable indicators of functional iron deficiency than ferritin alone.
Hemolysis has a specific laboratory signature
Hemolytic anemia produces elevated LDH, elevated indirect bilirubin, low haptoglobin, and an elevated reticulocyte count. Peripheral smear may show schistocytes (microangiopathic hemolysis), spherocytes (autoimmune hemolysis or hereditary spherocytosis), or sickle cells. The direct antiglobulin test (DAT/Coombs) distinguishes immune-mediated from non-immune hemolysis.
Clinical Pearl: Treating B12 deficiency with folate alone corrects the anemia but allows neurological damage to progress. Always check B12 before starting folate in macrocytic anemia.
Bottom Line
Use MCV to organize, reticulocyte count to separate hypoproliferative from hyperproliferative, and iron studies + smear to identify the mechanism.
MCV organizes the differential — microcytic, normocytic, macrocytic — but does not end it.
Reticulocyte count separates hypoproliferative (marrow not responding) from hyperproliferative (hemolysis or blood loss).
Mixed deficiencies (iron + B12/folate) can produce a normal MCV with elevated RDW — the normal average conceals two opposing processes.
Ferritin is an acute-phase reactant — a normal ferritin does not exclude iron deficiency in the setting of inflammation.
Hemolysis signature: elevated LDH, elevated indirect bilirubin, low haptoglobin, elevated reticulocytes, and smear findings.
Always check B12 before treating macrocytic anemia with folate — B12 deficiency causes neurological damage that folate treatment can mask.
Metformin impairs B12 absorption — check B12 in diabetic patients on long-term metformin.
EVIDENCE & REFERENCES
- Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. doi:10.1056/NEJMra1401038
- Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809